NYSE: $TAK A New Milestone in Targeted Oncology Takeda Pharmaceutical Company has recently announced encouraging top-line results from its Phase 2 clinical trial evaluating arcotatug tavatecan (TAK-921). This novel antibody-drug conjugate (ADC) is being developed as a potential treatment option for patients facing specific solid tumors. Key Findings from the Phase 2 Study The clinical…